KOL Identification

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A research tools start-up enlisted DeciBio to support their go-to-market strategy and activities for their novel sequencing technology by conducting pricing voice-of-customer research and evaluating potential pricing strategies

A healthcare technology startup wanted to conduct an assessment of potential go-to-market strategies for their AI analytical patient recruitment tool